Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Med Care. 2008 Sep;46(9):969–975. doi: 10.1097/MLR.0b013e318179253b

Table 2.

Adjusted* Empiric Bayes Geometric Mean (EBGM) Ratios comparing Relative Risks for Outcome Events for Current Celecoxib Users Versus Current Non-Selective Non Steroidal Anti-Inflammatory Drug (NS-NSAID) Users, Sorted by Significance based on Overlap of EB05/95 Confidence Intervals

Event (n) in
Celecoxib
Exposed		 Events (n) in
NS-NSAID
Exposed		 EBGM Ratio of
Celecoxib to
NS-NSAID** 		Ratio of Celecoxib EB05
to NS-NSAID EB95 CIs†
Acute myocardial Infarction (100) 31 20 1.91 1.08
Osteoarthritis (203) 57 53 1.47 0.97
Rehabilitation care; fitting of prostheses; and adjustment
of devices (254)		 41 35 1.49 0.92
Acute cerebrovascular disease (109) 28 22 1.62 0.91
Coronary atherosclerosis and other heart disease (101) 44 48 1.39 0.89

Numbers in parentheses () in the first column refer to the Agency for Health Research and Quality Clinical Classifications Software (CCS) event group

*

adjusted for age, gender, calendar year, and Charlson comorbidity index

**

estimates relative risk

†

ratios greater than 1.00 indicate that the confidence intervals of the two EGBM ratios did not overlap. All events with ratios > 0.85 are displayed.